• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Influenza B virus infections in Western Saxony, Germany in three consecutive seasons between 2015 and 2018: Analysis of molecular and clinical feature

tetano

Editor, Senior Moderator
Vaccine. 2019 Sep 11. pii: S0264-410X(19)31091-6. doi: 10.1016/j.vaccine.2019.08.027. [Epub ahead of print]
[h=1]Influenza B virus infections in Western Saxony, Germany in three consecutive seasons between 2015 and 2018: Analysis of molecular and clinical features.[/h] H?nemann M[SUP]1[/SUP], Martin D[SUP]2[/SUP], Pietsch C[SUP]2[/SUP], Maier M[SUP]2[/SUP], Bergs S[SUP]2[/SUP], Bieck E[SUP]3[/SUP], Liebert UG[SUP]2[/SUP].
[h=3]Author information[/h] 1 Institute of Virology, Leipzig University, Johannisallee 30, 04103 Leipzig, Germany. Electronic address: Mario.Hoenemann@medizin.uni-leipzig.de. 2 Institute of Virology, Leipzig University, Johannisallee 30, 04103 Leipzig, Germany. 3 Kreiskrankenhaus Torgau "J. Kentmann" gGmbH, 04860 Torgau, Germany.

[h=3]Abstract[/h] [h=4]BACKGROUND:[/h] The impact of annual influenza epidemics and prevailing strains varies worldwide and regional. The majority of vaccines used contained two influenza A strains and only one influenza B strain (trivalent vaccine).
[h=4]AIM:[/h] The aim of the study was to compare laboratory confirmed influenza B cases during three consecutive years with respect to vaccination history, clinical symptoms and molecular virology.
[h=4]METHODS:[/h] Partial HA gene sequences were analyzed for lineage determination and complete HA sequence in cases with reported vaccination and in fatal cases. Clinical data were retrieved from patient charts.
[h=4]FINDINGS:[/h] During the 2015/16 season, 75 influenza B cases were retrieved; 11 in 2016/17, and 274 in 2017/18. The frequency of Yamagata-lineage strains increased from 7.6% to 100%. No difference was detected in the relative frequency of co-morbidities in season 2017/18. 37.7% of the adult patients and 4.5% of pediatric patients were vaccinated against influenza.
[h=4]INTERPRETATION:[/h] Phylogenetically, Yamagata strains clustered similarly in 2017/2018 when compared to the previous two influenza seasons. While the relative frequency of influenza B cases differed, the clinical symptoms remained similar.
[h=4]CONCLUSION:[/h] World Health Organization recommendations for the use of tetravalent vaccines that contain two influenza B strains (Yamagata and Victoria) in addition to the two influenza A strains (H1N1 and H3N2) should be implemented in national vaccination guidelines.
[h=4]FUNDING:[/h] This research was partially supported by the Association of Sponsors and Friends of Leipzig University.
Copyright ? 2019 Elsevier Ltd. All rights reserved.


[h=4]KEYWORDS:[/h] Epidemiology; Influenza; Influenza B; Molecular epidemiology; Seasonal frequency; Victoria-like strains; Yamagata-like strains

PMID: 31521415 DOI: 10.1016/j.vaccine.2019.08.027
 
Back
Top Bottom